Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The trial proposed here attempts to reduce induction chemotherapy to phase I of standard
induction in patients with B-precursor ALL. Induction phase II will be replaced by
blinatumomab.
The initial treatment phase is followed by sequential chemotherapy and further blinatumomab
cycles.